Biogen Strikes A Deal With Isis For Antisense Technology
This article was originally published in The Pink Sheet Daily
Biogen has agreed to pay an upfront and milestones for an option to license Isis' Phase I antisense compound to treat a rare spinal disorder.
You may also be interested in...
The antisense company has made it clear that it will not pursue commercialization of its own drugs, but intends to partner out all of its assets, while still retaining the most advantageous economics. Its fourth agreement with Biogen Idec, a strategic collaboration, is the most extensive and lucrative to date with the partner.
The biotech’s latest tie-up is another validation of its technology that could help it garner further attention – and better economics – for some of its late-stage programs.
Spinal muscular atrophy is a rare disease that affects a small patient population of children. Isis is ready to move its compound into mid-stage testing after positive Phase I results, but the biotech isn’t the only company exploring the field.